Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

PR NewswireFeb 25 16:05 ET

Enliven Therapeutics: Promising Innovations in Tyrosine Kinase Inhibitors and Strategic Growth Plans Justify Buy Rating

TipRanksFeb 5 13:45 ET · Ratings

Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $39

Moomoo NewsFeb 4 01:32 ET · Ratings

Strong Buy Recommendation for Enliven Therapeutics Due to ELVN-001's High Selectivity and Promising Clinical Data

TipRanksFeb 4 00:35 ET

Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans

Yahoo FinanceJan 31 10:10 ET

Enliven Therapeutics Insider Sold Shares Worth $685,868, According to a Recent SEC Filing

MT NewswiresJan 10 17:37 ET

Insider Sale: CHIEF FINANCIAL OFFICER of $ELVN (ELVN) Sells 900 Shares

Quiver QuantitativeDec 31 17:31 ET

Clear Street Launches Healthcare & Biotechnology Equity Research

BusinesswireDec 17, 2024 14:00 ET

We're Hopeful That Enliven Therapeutics (NASDAQ:ELVN) Will Use Its Cash Wisely

Simply Wall StDec 14, 2024 09:13 ET

BTIG Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $42

Moomoo NewsDec 13, 2024 06:31 ET · Ratings

Enliven Therapeutics' ELVN-001: Navigating Competitive Challenges and Opportunities in the CML Market

TipRanksDec 10, 2024 13:55 ET

LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38

Moomoo NewsDec 9, 2024 08:31 ET · Ratings

JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $36

Moomoo NewsDec 5, 2024 11:35 ET · Ratings

Strong Buy Recommendation for Enliven Therapeutics: Promising Efficacy and Strategic Positioning in CML Market

TipRanksDec 5, 2024 10:27 ET

A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $36 to $40

Moomoo NewsNov 15, 2024 08:00 ET · Ratings

Express News | Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $40

BenzingaNov 15, 2024 07:19 ET

Enliven Therapeutics Reports Q3 Results and Clinical Progress

TipRanksNov 14, 2024 23:34 ET

Express News | Enliven Therapeutics Inc : Jefferies Raises Target Price to $33 From $32

ReutersNov 14, 2024 09:40 ET

Enliven Therapeutics: Promising Clinical Developments and Robust Financial Position Justify Buy Rating

TipRanksNov 13, 2024 18:35 ET

Express News | Enliven Therapeutics Inc: Current Cash, Cash Equivalents and Marketable Securities Expected to Provide Cash Runway Into Late 2026

ReutersNov 13, 2024 16:33 ET